Tag: Wegovy
-
Wegovy Moves Closer to PBS Listing for Adults with Obesity and Heart Disease
What is Wegovy and why the PBS listing matters Semaglutide, marketed as Wegovy, is a prescription medication designed to help adults with obesity lose weight and improve related health risks. The latest development from the Pharmaceutical Benefits Advisory Committee (PBAC) signals a significant step toward adding Wegovy to the Pharmaceutical Benefits Scheme (PBS) for people…
-
Wegovy Advances to PBS Listing: Semaglutide for Obesity and Heart Disease
Wegovy Moves Closer to PBS Listing Semaglutide, sold under the brand Wegovy, is nearing a pivotal milestone in Australia’s healthcare system. After preliminary recommendations from the Pharmaceutical Benefits Advisory Committee (PBAC), Wegovy could soon be available on the Pharmaceutical Benefits Scheme (PBS) for adults with established cardiovascular disease who also have obesity. This potential PBS…
-
Wegovy Moves Closer to PBS Listing for Australians with Obesity and Heart Risk
What’s happening with Wegovy and the PBS The anti-obesity drug Wegovy, whose active ingredient is semaglutide, has taken a significant step toward being added to Australia’s Pharmaceutical Benefits Scheme (PBS). The move signals a potential change in how adults living with obesity and established cardiovascular disease could access a proven therapy at a reduced price,…
-
Postpartum GLP-1 Drugs Use Increases, Study Finds
New Insight into Postpartum Medication Use Researchers in Denmark have uncovered a notable shift in how medications are used around and after pregnancy. While GLP-1 receptor agonists—popularly known by brand names like Ozempic and Wegovy—are primarily prescribed for diabetes and obesity, an emerging pattern shows more women receiving these drugs in the postpartum period. The…
-
Postpartum GLP-1 Drugs See Sharp Rise, Danish Study Finds
Overview: A Surprising Postpartum Trend A recent Danish study reveals a notable uptick in the prescription of GLP-1 drugs—widely known for aiding weight loss and blood sugar control—among women in the period following childbirth. Researchers were initially examining medication use during and after pregnancy, but the data soon highlighted a clear trend: more women are…
-
Overcoming Nausea: The Next Wave of Weight-Loss Drugs and Safer Experiences
Search for a ‘painless’ path to weight loss Millions of Americans have found success with prescription medications like Wegovy and Zepbound, which help reduce appetite and boost weight loss. Yet the journey isn’t the same for everyone. A common obstacle is nausea, a side effect that can range from mild discomfort to significant disruption in…
-
Brain scientists pursue nausea-free weight-loss drugs amid GLP-1 breakthroughs
Overview: The quest for nausea-free weight-loss medications Millions of Americans have achieved impressive weight loss with medications such as Wegovy and Zepbound, which target the body’s GLP-1 pathways to curb appetite and boost metabolic effects. Yet the journey with these drugs isn’t without rough edges. Nausea, vomiting, and other gastrointestinal side effects remain common early…
-
Brain scientists pursue nausea-free weight-loss drugs to improve outcomes
Overview: The quest for nausea-free weight-loss drugs Across the United States and beyond, millions have found success shedding pounds with medications such as Wegovy and Zepbound. These GLP-1 receptor agonists help reduce appetite and slow digestion, leading to meaningful weight loss for many individuals. Yet the journey isn’t without its rough edges. A sizable share…
-
Could Ozempic and Wegovy Cut Cancer Death Risk? Emerging Study Sparks Hope and Caution
New findings spark hope for GLP-1 drugs Recent research points to a surprising potential benefit of GLP-1 receptor agonists — the same class that includes weight‑loss medications Ozempic and Wegovy. A growing body of observational data suggests these drugs may be associated with improved cancer survival, particularly in colon cancer. While the results are intriguing,…
-
Could Ozempic and Wegovy Cut Colon Cancer Mortality? New Study Sparks Hope
Surprising findings from a new study In recent months, researchers have turned their attention to whether GLP-1 receptor agonists—drugs best known for aiding weight loss—might also influence cancer outcomes. Ozempic (semaglutide) and Wegovy (semaglutide for chronic weight management) belong to this class. A fresh analysis indicates that users of these medications could experience a meaningful…